Sildenafil for PNTM Infection

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Background:

• Pulmonary nontuberculous mycobacterial (PNTM) infection is caused by a common type of bacteria in the environment. Although PNTM infection is most common in people with lung diseases, it can also affect healthy people. It can be difficult to treat, and affects parts of the body other than the lungs. For example, PNTM may affect the cilia, the hair-like structures inside the nose and lungs that help move dirt and debris out of the body.

• Ciliary beat frequency (CBF) is a measurement of how fast cilia move. People with PNTM infection have a lower CBF than healthy people. Nitric oxide (NO) is a gas in the body that may affect CBF. People with PNTM infection produce lower amounts of NO in their noses than healthy people. Researchers want to see if a drug called sildenafil can increase NO production and CBF. If sildenafil can improve these measurements, it may be a useful treatment for PNTM infection.

Objectives:

• To study the effect of sildenafil on CBF and NO levels in people with PNTM infection.

Eligibility:

• Individuals at least 18 years of age who have PNTM infection.

• Participants must be enrolled in a related National Institutes of Health study on bacterial infections. The study is Natural History, Genetics, Phenotype and Treatment of Mycobacterial Infections.

Design:

• Participants will be screened with a physical exam and medical history. They will also have heart and lung function tests, as well as tests of NO production in the nose. They will provide samples of sputum and cells from inside the nose.

• Before the first study visit, participants will collect sputum samples for 24 hours. They will bring the samples to the study visit.

• At the first study visit, participants will have heart and lung function tests, as well as tests of NO production in the nose. They will provide blood, urine, sputum, and nasal cell samples. They will also receive sildenafil tablets to take at home.

• Participants will take sildenafil tablets three times a day.

• The second study visit will be 7 days after the first one. The tests from the first visit will be repeated. Participants will receive more sildenafil tablets to take on the same schedule as before.

• The third and final study visit will be 30 days after the first one. The tests from the first visit will be repeated. Participants will stop taking sildenafil at this visit.

• A follow-up phone call will be made about 2 weeks after the final study visit. This call will ask questions about quality of life and any symptoms or side effects of the study.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Sildenafil Citrate

Criteria

• INCLUSION CRITERIA:

1. Adults (18 years of age or older) with PNTM who are currently enrolled on the 01-I-0202 protocol Natural History, Genetics, Phenotype and Treatment of Mycobacterial Infections will be eligible for participation.

2. Subjects must have CBF in the range observed in subjects with PNTM (CBF 8.1 plus or minus 1.4 Hz or lower).

3. Women of childbearing potential must have a negative pregnancy test result.

4. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.

EXCLUSION CRITERIA:

1. Any subject who, in the opinion of the investigator, is unable or unwilling to comply with the study procedures, medication schedule, or study visits.

2. Use of nitrate medicines, other PDE inhibitors, or other drugs known to have unsafe interactions with sildenafil.

3. Known allergy to sildenafil.

4. History of the following:

1. Recurrent epistaxis.

2. Diabetes or impaired glucose intolerance (risk of retinal hemorrhage with sildenafil is highest in diabetics).

3. Portal hypertension.

4. Active pulmonary veno-occlusive disease (PVOD).

5. Use of daytime oxygen supplementation.

6. Unstable or uncontrolled hypertension.

5. Active retinopathy, history of retinal detachment, or hemorrhage.

6. Initiation of agents known to be potent CYP3A4 inhibitors or inducers (e.g., itraconazole, ritonavir, ketoconazole).

7. Any subject who, in the opinion of the investigator, may be at a greater risk of cardiovascular disease or congestive heart failure.

8. Breastfeeding.

Co-Enrollment Guidelines: Subjects will be co-enrolled in the 01-I-0202 protocol. They may also be enrolled in 07-I-0142 entitled Research Respiratory Tract Procedures .Co-enrollment in other trials is restricted, other than enrollment in observational studies or those evaluating the use of a licensed medication. Study staff should be notified of co-enrollment as it may require the approval of the principal investigator.